As the number of poorly soluble molecules entering development has increased over the years, new methods are needed to develop these molecules. Solid-state pharmaceutics is one approach to help get these compounds into early and late stage clinical trials. Solid forms such as polymorphs, salts, co-crystals, and amorphous dispersions have been used to change material properties and improve performance.
The symposium focused on the impact of polymorphism and solid state properties in pharmaceutical development. Case studies, characterization tools, and problem solving skills were discussed in-depth.
• The role of solid forms in the drug development process
• The use of co-crystals and amorphous dispersions in early and late phase projects
• Methods to produce materials with the desired properties
Crystal Pharmatech invited researchers from around the world in solid-state pharmaceutics including Kevin Roberts (drug crystallization researcher from the University of Leeds,), Nair Rodriguez-Hornedo (co-crystal researcher from the University of Michigan), Elizabeth Vadas (solid forms and formulation researcher from InSciTech Inc), and George Zografi (amorphous and amorphous dispersion researcher from the University of Wisconsin Madison). They shared the latest strategies on form screening, selection, and crystallization as well as recent developments in solid-state research with the symposium participants. These four researchers currently serve on the Crystal Pharmatech's Scientific Advisory Board.
The talks covered all aspects of materials science in the industry. "It was an academic event in solid-state research held in China", Dr. Alex Chen said, CEO of Crystal Pharmatech, "and we would like to thank Mettler-Toledo, Thermo Fisher Scientific, PANalytical, NIK Yang, Anton Paar, Glory Shine Technologies Ltd., Metrohm, DKSH and Germany Sympa for their sponsorship. The symposium was a huge success due to their strong support."
One of the missions of Crystal Pharmatech Co., Ltd is to guide Chinese pharmaceutical companies closing the research gap with western companies in the discovery and development of innovative drugs. This symposium was one way to meet that goal and Crystal Pharmatech will continue to hold these types of symposia.
Crystal Pharmatech Co., Ltd is the first technology-driven solid state research CRO based in China. The Crystal Pharmatech management team has more than 40 years of combined experience in top pharmaceutical companies focusing on solid state API and drug product development issues. Whether you are a top-tier innovator company or a pre-emerging biotech company, Crystal Pharmatech can handle all of your solid-state property needs. It offers a full range of services from being the solid state characterization arm of your company to consultation or training on a specific issue.